GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Centogene NV (NAS:CNTG) » Definitions » ROE % Adjusted to Book Value

Centogene NV (Centogene NV) ROE % Adjusted to Book Value : 0.00% (As of Jun. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Centogene NV ROE % Adjusted to Book Value?

Centogene NV's ROE % for the quarter that ended in Jun. 2023 was 0.00%. Centogene NV's PB Ratio for the quarter that ended in Jun. 2023 was N/A. Centogene NV's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2023 was N/A.


Centogene NV ROE % Adjusted to Book Value Historical Data

The historical data trend for Centogene NV's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Centogene NV ROE % Adjusted to Book Value Chart

Centogene NV Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
ROE % Adjusted to Book Value
Get a 7-Day Free Trial - -15.78 -12.19 -24.74 -53.68

Centogene NV Quarterly Data
Dec17 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Dec22 Jun23
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -36.84 -27.02 -52.21 - -

Competitive Comparison of Centogene NV's ROE % Adjusted to Book Value

For the Diagnostics & Research subindustry, Centogene NV's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Centogene NV's ROE % Adjusted to Book Value Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Centogene NV's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Centogene NV's ROE % Adjusted to Book Value falls into.



Centogene NV ROE % Adjusted to Book Value Calculation

Centogene NV's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2022 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-175.53% / 3.27
=-53.68%

Centogene NV's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Centogene NV ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Centogene NV's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Centogene NV (Centogene NV) Business Description

Traded in Other Exchanges
Address
Am Strande 7, Rostock, MV, DEU, 18055
Centogene NV is a United States-based company focused on transforming clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies. The company operates in three segments: pharmaceutical, diagnostics, and COVID-19. Its pharmaceutical segment provides a variety of services to its pharmaceutical partners, including early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring. Its clinical diagnostics segment provides targeted genetic sequencing and diagnostics services to patients.